Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph S Koopmeiners

Showing results (11-20 of 123) with videos related to

Pageof 13
Sort By:
Contemporary Clinical Trials|June 25, 2018
Efficacy/toxicity dose-finding using hierarchical modeling for multiple populationsKristen M Cunanan, Joseph S Koopmeiners
Mayo Clinic Proceedings|October 2, 2013
Trends in pneumonia hospitalizations in Hennepin County, Minnesota, 1999-2010Pui-Ying Iroh Tam, Joseph S Koopmeiners
Statistics in Medicine|January 13, 2012
Conditional estimation after a two-stage diagnostic biomarker study that allows early termination for futilityJoseph S Koopmeiners, Ziding Feng, Margaret Sullivan Pepe
Contemporary Clinical Trials|April 16, 2013
A two-stage Bayesian design with sample size reestimation and subgroup analysis for phase II binary response trialsWei Zhong, Joseph S Koopmeiners, Bradley P Carlin
Clinical Trials (London, England)|January 25, 2013
Discussion of 'small-sample behavior of novel phase I cancer trial designs' by Assaf P Oron and Peter D HoffBradley P Carlin, Wei Zhong, Joseph S Koopmeiners
Journal of Biopharmaceutical Statistics|March 11, 2014
Sample size and screening size trade-off in the presence of subgroups with different expected treatment effectsKyle D Rudser, Edward Bendert, Joseph S Koopmeiners
Statistics in Medicine|July 19, 2012
A trivariate continual reassessment method for phase I/II trials of toxicity, efficacy, and surrogate efficacyWei Zhong, Joseph S Koopmeiners, Bradley P Carlin
International Journal of Health Care Finance and Economics|March 14, 2007
Modeling and detecting potentially ruinous streaks in health expendituresJoseph S Koopmeiners, Bryan E Dowd, Bradley P Carlin
Statistics in Medicine|August 16, 2018
Efficiency and robustness of causal effect estimators when noncompliance is measured with errorJeffrey A Boatman, David M Vock, Joseph S Koopmeiners
Statistics in Medicine|June 22, 2021
Borrowing from supplemental sources to estimate causal effects from a primary data sourceJeffrey A Boatman, David M Vock, Joseph S Koopmeiners
Pageof 13

Showing results (11-20 of 123) with videos related to

Sort By:
Pageof 13
Contemporary Clinical Trials|June 25, 2018
Efficacy/toxicity dose-finding using hierarchical modeling for multiple populationsKristen M Cunanan, Joseph S Koopmeiners
Mayo Clinic Proceedings|October 2, 2013
Trends in pneumonia hospitalizations in Hennepin County, Minnesota, 1999-2010Pui-Ying Iroh Tam, Joseph S Koopmeiners
Statistics in Medicine|January 13, 2012
Conditional estimation after a two-stage diagnostic biomarker study that allows early termination for futilityJoseph S Koopmeiners, Ziding Feng, Margaret Sullivan Pepe
Contemporary Clinical Trials|April 16, 2013
A two-stage Bayesian design with sample size reestimation and subgroup analysis for phase II binary response trialsWei Zhong, Joseph S Koopmeiners, Bradley P Carlin
Clinical Trials (London, England)|January 25, 2013
Discussion of 'small-sample behavior of novel phase I cancer trial designs' by Assaf P Oron and Peter D HoffBradley P Carlin, Wei Zhong, Joseph S Koopmeiners
Journal of Biopharmaceutical Statistics|March 11, 2014
Sample size and screening size trade-off in the presence of subgroups with different expected treatment effectsKyle D Rudser, Edward Bendert, Joseph S Koopmeiners
Statistics in Medicine|July 19, 2012
A trivariate continual reassessment method for phase I/II trials of toxicity, efficacy, and surrogate efficacyWei Zhong, Joseph S Koopmeiners, Bradley P Carlin
International Journal of Health Care Finance and Economics|March 14, 2007
Modeling and detecting potentially ruinous streaks in health expendituresJoseph S Koopmeiners, Bryan E Dowd, Bradley P Carlin
Statistics in Medicine|August 16, 2018
Efficiency and robustness of causal effect estimators when noncompliance is measured with errorJeffrey A Boatman, David M Vock, Joseph S Koopmeiners
Statistics in Medicine|June 22, 2021
Borrowing from supplemental sources to estimate causal effects from a primary data sourceJeffrey A Boatman, David M Vock, Joseph S Koopmeiners
Pageof 13